• Views: in the last
  • 16Week
  • 9Month
  • 117Total

  • NJ A4138
  • Requires health benefits coverage for buprenorphine and buprenorphine/naloxone under certain conditions.
In Committee
Crossed OverPassedSignedDead/Failed/Vetoed
2016-2017 Regular Session
This bill requires health insurers (health, hospital and medical service corporations, commercial individual and group health insurers; health maintenance organizations, health benefits plans issued pursuant to the New Jersey Individual Health Coverage and Small Employer Health Benefits Programs, the State Health Benefits Program, and the School Employees' Health Benefits Program) to provide health benefits coverage for any expenses incurred by a covered person for the prescription and purchase of buprenorphine or buprenorphine/naloxone for the treatment of opioid addiction. The bill provides that coverage is not subject to any prior authorization, dollar limit, copayment, deductible, or coinsurance. Buprenorphine, commonly referred to by the brand name, Subutex, and buprenorphine/naloxone, commonly referred to by the brand name Suboxone, are medications used to treat opioid dependence. This bill seeks to make these medications more readily available and affordable for people with opioid dependence issues that have insurance and are seeking treatment.
Financial Institutions and Insurance
Introduced, Referred to Assembly Financial Institutions and Insurance Committee  (on 9/19/2016)
Date Chamber Action Description
9/19/2016 A Introduced, Referred to Assembly Financial Institutions and Insurance Committee
Date Motion Yea Nay Other
None specified